Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care Setting
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in retrospective analyses of insulin pen vs vial and syringe use in T2D samples, improved persistence and adherence, improved glycemic control, and lower rates of hypoglycemia were reported in the insulin pen groups.46–49”
From Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors (2016) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Research works printed but not linked: 20
- Huang, 2009, Projecting the future diabetes population size and related costs for the U. S., Diabetes Care, 32, 2225, 10.2337/dc09-0459 · DOI · Paper page
- Hoerger, 2008, Is glycemic control improving in U. S. adults?, Diabetes Care, 31, 81, 10.2337/dc07-1572 · DOI · Paper page
- Dodd, 2009, Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004, Curr Med Res Opin, 25, 1605, 10.1185/03007990902973300 · DOI · Paper page
- Oliveria, 2007, Barriers to the initiation of, and persistence with, insulin therapy, Curr Med Res Opin, 23, 3105, 10.1185/030079907X242638 · DOI
- Karter, 2010, Barriers to insulin initiation: the Translating Research Into Action for Diabetes insulin starts project, Diabetes Care, 33, 733, 10.2337/dc09-1184 · DOI · Paper page
- Korytkowski, 2003, A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus, Clin Ther, 25, 2836, 10.1016/S0149-2918(03)80337-5 · DOI · Paper page
- Summers, 2004, Preference for insulin delivery systems among current insulin users and nonusers, Clin Ther, 26, 1498, 10.1016/j.clinthera.2004.09.009 · DOI
- Goldstein, 2008, Pen devices to improve patient adherence with insulin therapy in type 2 diabetes, Postgrad Med, 120, 172, 10.3810/pgm.2008.09.1917 · DOI
- Ignaut, 2009, Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen, Diabetes Educ, 35, 789, 10.1177/0145721709340056 · DOI · Paper page
- Haak, 2007, Comparison of usability and patient preference for the new disposable insulin device SoloStar versus Flexpen, Lilly disposable pen, and a prototype pen: an open-label study, Clin Ther, 29, 650, 10.1016/j.clinthera.2007.04.003 · DOI
- Schwartz, 2008, Validation of the SoloSTAR insulin pen, Diabetes Technol Ther, 10, 351, 10.1089/dia.2008.0079 · DOI
- Hermanns, 2008, Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting, Diabetes Technol Ther, 10, 322, 10.1089/dia.2008.0035 · DOI
- Krzywon, 2010, Dosing accuracy of commonly used disposable insulin pens, Curr Med Res Opin, 26, 901, 10.1185/03007991003608878 · doi:10.1185/03007991003608878
- Rosenbaum, 1983, The central role of the propensity score in observational studies for causal effects, Biometrika, 70, 41, 10.1093/biomet/70.1.41 · DOI · Paper page
- Cooke, 2010, Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization, Curr Med Res Opin, 26, 231, 10.1185/03007990903421994 · DOI · Paper page
- Pawaskar, 2007, Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis, Clin Ther, 29, 1294, 10.1016/j.clinthera.2007.07.007 · DOI
- Hertz, 2005, Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance, Clin Ther, 27, 1064, 10.1016/j.clinthera.2005.07.009 · DOI · Paper page
- Rakel, 2009, Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy, Adv Ther, 26, 838, 10.1007/s12325-009-0061-2 · DOI
- Asakura, 2009, A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen), Diabetes Technol Ther, 11, 657, 10.1089/dia.2009.0006 · DOI · Paper page
- D'Agostino, 1998, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group, Stat Med, 17, 2265, 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
Polonsky, W., & Henry, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106821 · Cited by 784
A Systematic Review of Insulin Adherence Measures in Patients with Diabetes
Stolpe, S., Kroes, M. A., Webb, N., & Wisniewski, T. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.11.1224 · Cited by 77
Lasalvia, P., Barahona-Correa, J. E., Romero-Alvernia, D. M., Gil-Tamayo, S., Castañeda-Cardona, C., Bayona, J. G., Triana, J. J., Laserna, A. F., Mejía-Torres, M., Restrepo-Jimenez, P., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816633721 · Cited by 63
“A subanalysis was performed using the studies with similar definitions of discontinuation threshold.(14,15,18,26) The favorable tendency for”
MethodSlabaugh, S. L., Bouchard, J. R., Li, Y., Baltz, J. C., Meah, Y. A., & Moretz, D. C. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0266-5 · Cited by 41
Ahmann, A., Szeinbach, S. L., Gill, J., Traylor, L., & Garg, S. K. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0172 · Cited by 39
Self-citation
Metadata
- Authors
- Davis, S. N., Wei, W., & Garg, S.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 17
- Issue
- 6
- Pages
- 845-852
- ISSN
- 1530-891X
- Cited by
- 31
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care Setting. https://app.cochat.ai/papers/10.4158/ep10401.or
- The paper
- Davis, S. N., Wei, W., & Garg, S. (2011). Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care Setting. Endocrine Practice. https://doi.org/10.4158/ep10401.or
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.